Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

Jan 14, 2018Molecular cancer

Potential of engineered immune cells to treat solid tumors

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Adoptive cell immunotherapy using CARs specific for CD19 has shown remarkable responses in some patients with hematological malignancies.

CAR-T cell therapy has limited clinical efficacy in treating solid tumors.
Immunosuppression in solid tumors may arise from multiple mechanisms.
Strategies to enhance T cell effectiveness in solid tumors are being explored.
The review summarizes current approaches to overcome the immunosuppressive environment.

AI simplified

The potential for adoptive cell immunotherapy as a treatment against cancers has been demonstrated by the remarkable response in some patients with hematological malignancies using autologous T cells endowed with chimeric antigen receptors (CARs) specific for CD19. Clinical efficacy of CAR-T cell therapy for the treatment of solid tumors, however, is rare due to physical and biochemical factors. This review focuses on different aspects of multiple mechanisms of immunosuppression in solid tumors. We characterize the current state of CAR-modified T cell therapy and summarize the various strategies to combat the immunosuppressive microenvironment of solid tumors, with the aim of promoting T cell cytotoxicity and enhancing tumor cell eradication.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief